

Formulation, Development and Characterization of Osmotic Tablets Containing Acyclovir

Harshkumar Brahmbhatt¹, Lavande J P², *Vikas Vasant Patil³, Imran A Sheikh⁴, Rohit⁵, Chamundeswara Srinivasa Akash kalla⁶, Kaynaz Hussain⁷, Rajeev Ranjan⁸

¹Department of Pharmacy, Sumandeep Vidyapeeth Deemed to be University
At & Po. Pipariya, Taluka: Waghodiya, Vadodara, Gujarat 391760

²Fabtech College Of Pharmacy, Sangola, Pandharpur Road, Gate No. 565/1, Sangola, Solapur, Maharashtra. 413307

³KVPS's Institute of Pharmaceutical Education, Boradi, Shirpur, Dhule, Maharashtra. 425428

⁴Anjuman I Islam's Kalsekar Technical Campus School of Pharmacy, Plot No.2 And 3 Sector 16, Khandagao, New Panvel, Navi Mumbai, Maharashtra, India.

⁵RKSD College of Pharmacy, Ambala Road , Kaithal, Haryana. 136027

⁶Department of Pharmaceutics and Drug Delivery, School of Pharmacy, The University of Mississippi, USA. 38677

⁷School of pharmaceutical sciences, University of Science and Technology Meghalaya. 793101

⁸University Department of Chemistry, DSPM University, Morhabadi, Ranchi. 834008

Corresponding Author

*Vikas Vasant Patil³

³KVPS's Institute of Pharmaceutical Education, Boradi, Shirpur, Dhule, Maharashtra. 425428

Abstract: The primary objective of this review was to make and test permeable osmotic tablets that can expand with controlled porosity for the treatment of herpes simplex. This formulation strives to improve bioavailability, reduce useful organ recurrence, eliminate unwanted design drugs, and improve patient consistency. Acyclovir is a manufactured simple of a purine nucleoside that is especially initiated by thymidine kinase, which is delivered by the Herpes Simplex Infection (HSV). It hinders viral DNA polymerases and fills in as a chain eliminator. Direct pressure was the strategy used to make the tablets, which were then profound covered to make a sum of nine formulations (F1-F9). The produced granules' flow and compression properties were assessed before compression. Also considered for the in vitro drug release investigation was a prepared osmotic drug delivery device. During pill disintegration, the coating did not exhibit any signs of leaking and remained stable. The range of the coated tablet's weight increase percentage was determined to be 1.98–2.40%. Semipermeable membrane has a 240 m thickness and can tolerate pressure during disintegration. In addition, checking electron microscopy (SEM) was utilized to look at the surface design of the broke up covering film and to identify the arrangement of pores on the film. According to the prescribed ICH requirements, accelerated stability experiments for the improved formulation were carried out for one month. When formulas were examined for drug concentration and in vitro dissolution experiments, it was shown that they remained stable for a month.

Keywords: Osmotic Tablets, Formulation, Acyclovir, Development, Characterization.

1. Introduction

Drug-active and non-drug components are combined in dosage formulations. They come in a variety of forms depending on how they are administered. There are three types of dose forms: liquid, solid, and semisolid. Osmotic pressure is used as the energy source in osmotically regulated oral drug delivery systems (OCODDS) for the controlled distribution of medications. The pH and hydrodynamic states of the gastro-digestive system (GIT) affect the medication discharge from these frameworks, and delivery attributes might be promptly different by changing the conveyance framework's settings. The oral bioavailability of meds that have site-explicit retention from the stomach or upper part of the small digestive tract is improved by keeping the portion structure in the stomach for a more extended timeframe. In this way, various techniques — including mucoadhesive formulations, enlarging and

growing frameworks, and drifting or light frameworks — have been investigated to keep the portion structure in the stomach. The possibility of light planning gives a direct strategy to expanding the measurements structure's visit in the stomach and guaranteeing delayed drug discharge Acyclovir (ACYCLOVIR) is the most widely used medicine for the treatment of diseases such as cutaneous, vaginal, chickenpox, Varicella Zoster, and Herpes keratitis. It is the main substance to support the treatment of Herpes simplex infection disease. Currently, it is available in 200mg containers, 400mg, 800mg, and 200mg tablets. It is also available in a suspension for use orally, intravenously, and effectively.

The most common dosage for oral acyclovir is five 200 mg pills per day. In addition, immunocompetent individuals with the currently available conventional medication have a number of disadvantages, including limited bioavailability (10-20%) and very unpredictable absorption. Additionally, the bioavailability decreased with an increase in dosage. In the current research, floating Gelucire 43=01 acyclovir granules with a longer stomach residence duration were created using the melt granulation process. This ought to further develop acyclovir ingestion and bioavailability. Actual attributes, percent yield, drug content, in vitro ability to drift, and in vitro drug arrival of the delivered granules were evaluated.

2. Literature Review

As indicated by Pradeep B. et al. (2010), acyclovir is utilized against inhibitor of herpes infection securely and effectively since it is explicit and particular. Because of its limited bioavailability, the medication is absorbed poorly. The prodrug of Acyclovir, Valacyclovir is used to treat both varicella zoster and herpes simplex. It is effective after oral dosing because the liver and gastrointestinal system may convert it into acyclovir more quickly.

A technique for the separation of acyclovir and related antiviral chemicals was described by Loregiana, A. et al. in 2001. This technique uses carbon silica columns from 7.5 to 1830 cm for separation and analysis, the two of which should be finished in under 10 minutes at a low pace of 1.0 to 1.5 ml/min. Its essential absorbance at 260-285 nm, 375-380 nm, and 250-254 nm, separately. While taking a gander at natural liquids, the LOD is 0.310ng/ml. LOD is 0.15 g/ml, and the alignment linearity was demonstrated to be direct in the scope of 0.2-20.0 ng/ml. A straightforward and affordable spectrophotometric approach for determining the presence of acyclovir in bulk drugs and formulations was published by Basavaiah K. et al. in 2002. Beer's law is followed by coloured analytes and excipients with a maximum absorption at 760 nm and concentrations between 50 and 450 g/ml. Molar Absorption

Acyclovir will increase in molar absorbance as the concentration increases, as shown by the correlation coefficient (0.9998) ($n = 9$). Sand ell sensitivity (1.65102 l /mol/cm) and Sand ell molar absorption (1.36 g /cm²) were reported. The regression line's slope and correlation coefficient are 8.33 103 and 6.87 104, respectively. The LOQ was 18.95g/ml, whereas the LOD was 5.68g/ml.

Spectrophotometric method for acyclovir determinations in analytical dosage forms Gandhi P., et al (2006) A spectrophotometric technique was developed to analyze acyclovir in both pharmaceutical dose and bulk form. Acyclovir's which brought about the fixation scope of 2-20 g/ml, submitted to Brew's regulation. These discoveries permitted recuperation tests and factual investigation to affirm the procedure utilized for examination.

The strategy for investigating acyclovir and acebutolol hydrochloride by spectrofluorimetric and spectrotometric techniques was revealed by Ayad M. et al. in 2007. The techniques fundamentally incorporate oxidizing the or absorbance = 320 nm (Spectrophotometric = 250 nm) This approach can be predicted with Brew's control in scopes of (2) to 8, (1) to 7, (0.25-2.51-2.51 g/cm acyclovir), and (2.51-3.51 g/ml acetylvole hydrochloride) separately. With remarkable recoveries, this approach distinguishes the selected drugs within their drug arrangements.

A close-to-infrared (NIR) spectroscopy approach for quantitative assays in plasma was described in Liyan Y., et al., 2008. The goal of this study was to break down plasma levels of acetylcholine. The rationale for this study was to evaluate the adequacy of NIRs. The 6-factor (PLS) alignment was used to determine the centralization (centralization) of acetyl-choline in the plasma assays. The range in

line (RLS) in the locale (6102–5450) for every cm was used. For acetylcholine, the RTG (RSDof conjecture) that was actually observed was (1.21). The PLS – NIRS process is designed to break down (120) examples per hour without the need for test arrangement, and to reduce squander creation.

3. Materials And Methods

3.1. Materials

A free illustration of acyclovir taken from Acrolab in Bangalore. Packaging was purchased from Loba chem HCl and Merck Strongpoints Ltd. In Mumbai:

hydroxypropyl methylcellulose LV 50 (HPMC LV 50), sodium lauryl sulfate (SLS), microcrystalline cellulose (MCC), polyethylene glycol 400 (Stake 400), sorbitol, dibutyl phthalate, potassium chloride, assurance of the destructive capability of cellulose and potassium dihydrogen orthophosphate.

3.2. Methods

3.2.1. Design of the Acyclovir Core Tablet:

Acyclovir focus tablets were made utilizing the prompt tension cycle and various groupings of osmogen (potassium chloride) and HPMC LV 50. Both the drug and the excipient are placed in the digital channel. 40. All the trifles are put in the mortar and pestle. The powder and magnesium stearate are mixed with the main mixture, then passed through the digital channel. 80. Rotary tablet presses are used to pack powder mixtures. Table 1 records the attachments along with their capacities, while Table 2 records the portions of the core tablet formulation

Table 1: Formulation Plan of Center Tablet

S.No.	Name of Fixing	Capability of Fixing
1	Acyclovir	active component of a medication
2	Cellulose microcrystalline	Binder/polymer
3	Methyl hydroxypropyl cellulose	polymer
4	chloride of potassium	Osmogent
5	Lauryl sulfate sodium	Wicking agent
6	stearate of magnesium	lubricant
7	Talc	Glidant

Table 2: Structure of Center Tablet Formulation

Code of formulation	1	2	3	4	5	6	7	F8	9
Drug	202	200	300	250	200	200	150	50	200
Cellulose microcrystalline	189	100	250	175	250	80	60	120	100
Cellulose hydroxypropyl methyl	100	75	50	100	100	60	75	100	65
Chloride of Potassium	50	80	30	85	150	90	60	200	15
Lauryl Sulfate Sodium	10	20	60	50	60	30	100	10	20
Magnesium Stearate	30	20	10	30	10	80	200	30	10
Total Weight	581	495	700	690	770	540	645	510	410




Figure1:Structure ofCentre Tablet Formulation

3.2.2. Coating of Acyclovir Core Osmotic Tablet

To make the covering arrangement, 2 grams of cellulose acetic acid derivation were broken up in 100 ml of water. A 2% w/v arrangement of cellulose acetic acid derivation, isopropyl liquor, and CH₃)₂CO were delivered. Dibutyl phthalate, a plasticizer, and Stake 400, a transition controller, were added as arrangements. Finally, sorbitol, a pore-outlining subject matter expert, was added, and the arrangement was upset for 15 minutes.

3.2.3. Coating Technique

The tablets were warmed in a 45°F (0.5°C) oven for 15 minutes before being used for covering. Container covering or the plunge covering technique was utilized to apply the tablet covering. The tablets were dunk covered in polymer arrangements made of cellulose acetic acid derivation that had been broken down in an answer of CH₃)₂CO and isopropyl liquor that likewise incorporated a plasticizer and pore-shaping specialist. Subsequent to covering, the tablets went through a short-term 40°C drying cycle to dispense with any excess dissolvable.

Table 3 lists the chemicals and their functions, whereas Table 4 lists the components of the coating formulation.

Table 3:Structure of Covering Formulation

Formulation Code	PEG 400 (ml)	Sorbitol (mg)	Dibutyl phthalate (ml)
1	1.345	0.5	0.7
2	1.345	0.5	1.3
3	1.345	1.1	0.9
4	1.345	1.1	1.3
5	1.699	0.5	1.3
6	1.699	0.5	0.9
7	1.699	0.1	1.3
8	1.699	0.1	0.9




Figure 2:Composition of Coating Formulation

4. Results And Discussion

4.1. Drug-Excipients Interaction Studies

Using a FTIR spectrometer, the IR spectra of the remedy and its genuine mix were acquired. For the affiliation assessments, the FT-IR spectra of the unadulterated cure and its veritable blend were gathered. This revelation emphatically shows that there is no huge cooperation between the medication and excipients, and the medication keeps on existing in its regular structure. Figure 2 analyzes the impacts of medications and actual blends.




Figure 3: Comparison between the drug's physical mixture and its fast peaks.

4.2. Micromeritic Evaluation Characterization

4.2.1. Evaluation of Granules

Known techniques were used to examine the flow characteristics of the granules. 10. The channel strategy was utilized to compute the point of rest. The mass, tapped, and compressibility files were processed.

4.2.2. Evaluation of Granules

The pre-arranged center tablets went through assessments for different variables, including generally attributes, hardness, thickness, and consistency of medication content.

4.2.3. Evaluation of Coated Tablet

The covered tablets were surveyed in view of various variables, including visual personality, weight increment of the center tablet, layer thickness, and film surface shape.

4.3. General Characteristic

The central tablets had a concave form, were white, and had a smooth surface.

4.3.1. Thickness

The thickness, which was deemed to be adequate, was in the range of 5.396-5.776 mm.

4.3.2. Hardness

The scope of 5.3-6.1 kg/still up in the air to be appropriate for direct pressure of the hardness.

4.3.3. Friability

All clumps' friability was in the 0.45 to 0.61% territory, which is inside the IP furthest reaches of under 1%. This was considered to be sufficient.

4.3.4. Weight Inconsistency

Twenty pills from each formulation were ingested, and the mean weight fluctuation was determined to be in IP compliance.

4.3.5. Content Consistency

The scope of 98.96 to 99.74% for drug content consistency across all groups was inside adequate limits.

4.4. In vitro dissolution research

All formulations introduced center around exposing the USP gadget to for two fundamental hours, trailed by PBS (pH 6.8) kept up with at 37.0 °C at 50 rpm. After the obvious reaches, the broke up medium measure was killed and supplanted with an indistinguishable extent of the spic and span medium. After adequate cooling with the examples were secluded and the absorbance at 253 nm was assessed to close whether medication discharge happened. substance or not. Equation F2 addressed the best medication discharge at the foreordained season, all things considered, as shown by the all-out relative medication discharge rate. Figure 3 shows the disintegration information for.




Figure 4: Cummulative Rate of Drug Release by Formulation

4.5. Thickness Of Film

The film was separated from the tablets after complete disintegration, and it was then dried at 40°C for one hour. Semipermeable membrane had a 240 m thickness and could tolerate pressure during disintegration. The coating thickness is seen in Figure 4.




Figure 5: Layer of Coating After Dissolution

4.6. Scanning Electron Microscopy

After the coated layer had dissolved, the surface morphology had been examined by filtering electron microscopy. Figure 5 portrays the SEM result, which exhibits the smooth surface layer and opening creation in the film.




Figure 6: Sem Microphotograph of Layer, Showing Development of Pores

As indicated by ICH (Global Meeting of Harmonization) controls, The improved formulation's accelerated steadiness test was conducted for one month at 40°C and 75% RH. As per the solidness concentrate on discoveries in Table 5, the boundaries as a whole—including by and large appearance, hardness, and dynamic part satisfied were inside OK cutoff points.

Table4:Osmotic Tablet Stability Study of Optimised Batch

Parameters	Time		
	0 day	15 days	30 days
physical attributes	White	White	White
Weight (mg)	545.6±1.91	545.4±7.95	545.0±1.95
Hardness (kg/cm ²)	5.8±0.039	5.8±1025	5.8±4.222
% Drug content	95.98±0.05	95.93±0.07	95.98±0.08

5. Conclusion

In the current study, a direct compression approach was used to effectively produce an acyclovir swellable controlled porosity osmotic tablet. Out of all nine formulations, formulation F2 outperformed the other batches in terms of performance. The covering formulation C7 has sufficient strength and structures a level surface, medication discharge and 98.92 solution discharges. The coated tablet gained % weight and the coating were stable throughout tablet breakdown, both of which are required for controlled release formulations. Acyclovir-containing drifting granules of Gelucire 43=01 have been made utilizing the soften granulation cycle to drag out their visit in the stomach, which might work on the medication's retention and bioavailability. When employed at an ideal concentration, Gelucire 43=01's hydrophobic qualities and simplicity of administration offer the optimum drug release profile. Over an 8-hour period, the grains keep the floating in place. According to statistical analysis, a suitable factorial design and optimization strategy may be used to make floating granules that have the largest in vitro floating ability while delaying the drug release from the granules.

Acyclovir was coordinated into various and cosurfactant, independently. The case of the drug's conveyance was impacted by how much water in the body. A powerful examination of the conveyance data uncovered that non-Fickian transport was the conveyance framework.

References

- [1] Ayad M., Abdellatef H., Henawee M. and Sayed H. (2007), *Spectrophotometric and spectrofluorimetric methods for analysis of acyclovir and acebutolol hydrochloride*, *Spectrochimica Acta Part A*, 66, 106–110.
- [2] Basavaiah K. and Prameela H.C. (2002), *Simple spectrophotometric determination of acyclovir in bulk drug and formulations*, *Il Farmaco*, 57, 443–449.
- [3] Dinanath Gaikwad, Jadhav RT, Amol Limkar, Sangeeta, Kisan Bobe, Manoj Patil, Trushali Khade, Bhaskar Gavitre, Vivek Kulkarni, Uday Gaikwad: *Formulation and Evaluation of Sustained Release Tablet of Aceclofenac by Film Coating*. *International Journal of Research in Pharmaceutical and Biomedical Sciences* Jan – Mar 2011; 2: 310-318.
- [4] G Zentner, Rork and K Himmelstein: *The controlled porosity osmotic pump*. *J Cont Release*. 1985; 1:269-282.
- [5] Gandhi P., Momin N., Kharade S., Konapure N. and Kuchekar B. (2006), *Spectrophotometric Estimation of Acyclovir in Pharmaceutical Dosage Forms*, *Indian J. Pharm. Sci.*, 68 (4), 516-517.
- [6] HC Ansel, LV Allen and CG Popovich: *In Pharmaceutical dosage form and drug delivery system*. B.I. Wavery Pvt. Ltd. New Delhi. 2000; 66:60-61.
- [7] JalonDe, E. G., M. J. Blanco-Prieto, V. Ygartua, and V. Santoyo. 2003. *Increased efficacy of acyclovir-loaded microparticles against herpes simplex virus type 1 in cell culture*. *European Journal of Pharmaceutics and Biopharmaceutics* 56:183–187
- [8] Jaypee brother medical publication (P) Ltd.P:769-79. Leon Lachman, Liberman, Kanig JL: *The theory and practice of industrial pharmacy*. 3rd ed., Varghese publishing house.1987; 171-196
- [9] K D Tripathi: *Essential of medical pharmacology*.2008; 6th edition New Delhi.
- [10] Liyan Y. and Xiang B. (2008), *Quantitative determination of acyclovir in plasma by near infrared spectroscopy*, *Microchemical Journal*, 90, 63–66.

- [11] Loregiana, A., Gattib R., Palu G. and Paloc E. (2001), *Separation methods for acyclovir and related antiviral compounds*, *Journal of Chromatography B*, 764, 289–311.
- [12] Pradeep B., Nagamadhu M., Banj D., Shekhar k., Bindu Madhavi B. and Arjun G. (2010), *Valacyclovir: Development, Treatment and Pharmacokinetics*, *International Journal of Applied Biology and Pharmaceutical Technology*, 1(3),1076-1083.
- [13] Robinson JR(Ed): *Sustained and controlled release drug delivery system*. Marcel Dekker. New York. Second ed; 1980: p.no 213.
- [14] S Vyas, Khar RK: *Controlled Drug Delivery Concepts and Advances*. 3th ed. Vallabh Prakashan 2005; P: 412- 446.
- [15] Theeuwes: *Microporous-semipermeable laminated osmotic system*.US Patent.1978; 4,256,108.
- [16] Dhabliya, D., & Dhabliya, R. (2019). *Key characteristics and components of cloud computing*. *International Journal of Control and Automation*, 12(6 Special Issue), 12-18. Retrieved from www.scopus.com.
- [17] Dhabliya, D., & Parvez, A. (2019). *Protocol and its benefits for secure shell*. *International Journal of Control and Automation*, 12(6 Special Issue), 19-23. Retrieved from www.scopus.com
- [18] Dhabliya, D., & Sharma, R. (2019). *Cloud computing based mobile devices for distributed computing*. *International Journal of Control and Automation*, 12(6 Special Issue), 1-4. doi:10.33832/ijca.2019.12.6.01